SEARL in a notice informed that it has concluded an exclusive licensing & supply agreement with Livzon Mapharm Inc for the “recombinant novel coronavirus vaccine(V-01)’ which also covers manufacturing transition of (V-01) in Pakistan.
Home Stock Market SEARL has concluded an exclusive licensing & supply agreement with Livzon Mapharm...
Sign in
Welcome! Log into your account
Forgot your password? Get help
Password recovery
Recover your password
A password will be e-mailed to you.